Development of the Sm14/GLA-SE - schistosomiasis vaccine candidate: An open, not placebo-controlled, standardized dose immunization phase Ib clinical trial targeting healthy young women

We report the successful closure of Phase I clinical trials of the Schistosoma mansoni 14 kDa fatty acid-binding protein (Sm14) + glucopyranosyl lipid A in squalene emulsion (GLA-SE) vaccine candidate against human Schistosomiasis, comprising Phases Ia and Ib. Shown here are the results of Phase Ib, an open, not placebo-controlled, standardized-dose immunization trial, involving 10 healthy 18-49 years old women submitted to the same clinical protocol and the same batch of cGMP Sm14+GLA-SE used in Phase Ia, which was one on men. Fifty {micro}g Sm14 protein plus 10 {micro}g GLA-SE per dose were given intramuscularly thrice at 30-day intervals. Participants were assessed clinically, biochemically, and immunologically for up to 120 days. In preambular experiments involving vaccinated pregnant female rabbits, we did not find any toxicological feature either in offspring or mothers, as ascertained by histopathology and biochemical parameters. The vaccine induced adaptive immunity in the animals, as defined by the detection of anti-Sm14 antibodies in the sera. In women, neither serious nor light adverse events were observed. Sm14+GLA-SE vaccination induced high titers of anti-Sm14 serum IgG antibody production. Total anti-IgG serum levels remained high 120 days after the first vaccination dose. Significant increases in Sm14-specific total IgG, IgG1, and IgG3 were observed 30 days after the first vaccination, with specific IgG2 and IgG4 after 60 days. Sm14+GLA-SE vaccination also elicited robust cytokine responses with increased TNF, IFN{gamma}, and IL-2 profiles in all female vaccinees on days 90 and 120. As in Phase Ia, the Sm14+GLA-SE vaccine was shown to be strongly immunogenic and well tolerated. The completion of Phase I clinical trials performed to the highest standards set by the Good Clinical Research Practice (GCP) standards and pre-clinical data in pregnant rabbits enabled the vaccine candidate to proceed to Phase II clinical trials in endemic areas.


67
Schistosomiasis is a parasitic disease that affects populations living in areas with very poor 68 sanitary conditions where they get infected through the contact with contaminated water during 69 their daily working, domestic or leisure activities. Children are the main target of the infection 70 that strongly compromises their physical and cognitive development [1,2]. Such a feature turns 71 schistosomiasis, not only into a disease resulting from poverty, but also into a backwardness  Presently, the so-called Mass Drug Administration (MDA) program against schistosomiasis is 82 the strategy adopted by WHO in which populations in endemic areas are treated annually with 83 Praziquantel without previous diagnosis. Such strategy actually led to an improvement with 84 regards to the pathology associated to schistosomiasis [5]. However, the world prevalence is 85 still as high as it has always been and the Disability-Adjusted Life Years (DALYs) value , 86 which is an important tool to assess the impact of diseases, has increased [6]. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 19, 2022.    is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint    is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  166 The study in pregnant rabbits was conducted in accordance with the protocol provided by    All animals had the inoculation area shaved and marked before each immunizing dose, to 186 assess further possible local reactions that might include erythema and edema; both being 187 scored according to standard protocols [24]. Daily clinical evaluation of each animal was . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 19, 2022. ; https://doi.org/10.1101/2022.08.17.22278904 doi: medRxiv preprint 188 performed and duly recorded in the individual data chart by a veterinarian. Parameters such as 189 occurrence of abortion, stress level, appetite, manure, and skin/local reactions at inoculations 190 sites, were evaluated and measured. Body weight was determined at the beginning and at the 191 end of the study. Food and water consumption was recorded every day individually.

192
Biochemical and blood cell evaluation was done following current laboratory practices and 193 included liver, renal and pancreatic functions, as well as red and white blood cell countings and 194 coagulation parameters.

195
All animals were anesthetized with thiopental sodium and euthanized by exsanguination.

196
Detailed anatomopathological analyses of all organs were carried out following euthanasia. All is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 19, 2022. ; https://doi.org/10.1101/2022.08.17.22278904 doi: medRxiv preprint 213 All statistical analyses were carried out by using GraphPad Prism version 4.0 software. All

223
In addition, tests were monitored by TECHTRIALS, an independent research company, and 224 data was deposited into a Data Bank [28] under the code NCT01154049. were selected for the trial, and their demographic characteristics are depicted in S1 Table. . CC-BY 4.0 International license It is made available under a perpetuity.
is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 19, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint   is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  for normal pregnant rabbits [32]. The ovaries of all 24 animals were consistent with normal 292 appearance. All analyzed uteri were comparable with a normal pregnant uterus for outbred 293 rabbits according to established criteria [33]. The microscopic results showed that the ovaries 294 of all 24 pregnant rabbits had follicles at different stages of development in the cortical region, 295 usual interstitial stromal glands and containing varying numbers of corpora lutea (Figure 1).

296
There was no statistically significant difference for any of the parameters assessed in this study 297 between vaccinated and control animals. Table 1 shows that the duration of pregnancy, the   is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint   is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

Adverse events related to the injection of vaccine: reactions at the site of the injection and
The copyright holder for this this version posted August 19, 2022. ; https://doi.org/10.1101/2022.08.17.22278904 doi: medRxiv preprint 351 outside of the normal range were evaluated and, given that no abnormal laboratory findings or 352 clinical symptoms were observed, they were all considered as non-clinically significant (that is, 353 most probably not related to the vaccine). These data show that the vaccine produced very few 354 adverse effects and all the observed events were local and mild (Tables 3 and 4).  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  Table 4. 365

Type of Test Findings * (#: Participant study number; RV= Reference Values) Toxicity Evaluation
Hematologic tests MCV (fl) #3: slightly below lower limit at D120 No toxicity observed.
No toxicity observed.
Eosinophil (%) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 19, 2022.
No toxicity observed.
Urea (mg/dl) No values were above the LR RV. No toxicity observed.

Other blood test
Calcitonin (pg/mL) No values were above the LR RV No toxicity observed.

Abdomen physical exam
Abnormalities None observed. No toxicity observed. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  (Fig 3). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint   is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 19, 2022.    is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted August 19, 2022. ; https://doi.org/10.1101/2022.08.17.22278904 doi: medRxiv preprint